Valuation Eurofins Scientific SE Deutsche Boerse AG
Stocks
ESF
FR0000038259
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.62 EUR | -1.07% |
|
-4.59% | -9.73% |
| 06-30 | NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation |  |
| 06-23 | Eurofins Scientific SE acquired Weatherbys Scientific. | CI |
Company Valuation: Eurofins Scientific SE
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 20,893 | 12,900 | 11,336 | 9,273 | 11,036 | 12,282 | - | - |
| Change | - | -38.26% | -12.13% | -18.2% | 19.02% | 11.28% | - | - |
| Enterprise Value (EV) 1 | 23,132 | 15,739 | 14,041 | 12,269 | 14,677 | 15,724 | 15,366 | 14,995 |
| Change | - | -31.96% | -10.79% | -12.62% | 19.63% | 7.13% | -2.27% | -2.41% |
| P/E | 27.8x | 22.2x | 45.4x | 26.9x | 28x | 24.4x | 18.7x | 15.7x |
| PBR | 4.49x | 2.7x | 2.24x | 1.73x | 2.56x | 2.56x | 2.31x | 2.11x |
| PEG | - | -1x | -0.8x | 0.7x | 1.3x | 0.8x | 0.6x | 0.8x |
| Capitalization / Revenue | 3.11x | 1.92x | 1.74x | 1.33x | 1.51x | 1.62x | 1.52x | 1.42x |
| EV / Revenue | 3.44x | 2.34x | 2.16x | 1.77x | 2.01x | 2.07x | 1.9x | 1.73x |
| EV / EBITDA | 12.2x | 10.4x | 10.3x | 7.91x | 8.94x | 9.09x | 8.1x | 7.22x |
| EV / EBIT | 15.7x | 15.2x | 16.7x | 12.1x | 13.6x | 14.4x | 12.4x | 10.8x |
| EV / FCF | 22.8x | 23.2x | 29.6x | 15.3x | 16.7x | 21.8x | 17.5x | 15.5x |
| FCF Yield | 4.39% | 4.3% | 3.38% | 6.53% | 5.97% | 4.58% | 5.73% | 6.47% |
| Dividend per Share 2 | 1 | 1 | 0.5 | 0.5 | 0.72 | 0.7704 | 0.8987 | 0.9605 |
| Rate of return | 0.92% | 1.49% | 0.85% | 1.01% | 1.15% | 1.1% | 1.28% | 1.37% |
| EPS 2 | 3.91 | 3.02 | 1.3 | 1.83 | 2.23 | 2.88 | 3.75 | 4.473 |
| Distribution rate | 25.6% | 33.1% | 38.5% | 27.3% | 32.3% | 26.8% | 24% | 21.5% |
| Net sales 1 | 6,718 | 6,712 | 6,515 | 6,951 | 7,296 | 7,600 | 8,074 | 8,666 |
| EBITDA 1 | 1,902 | 1,513 | 1,364 | 1,552 | 1,641 | 1,729 | 1,896 | 2,078 |
| EBIT 1 | 1,473 | 1,037 | 842 | 1,017 | 1,079 | 1,093 | 1,240 | 1,392 |
| Net income 1 | 783 | 606 | 310 | 406 | 475 | 516.7 | 676.2 | 795.9 |
| Net Debt 1 | 2,239 | 2,839 | 2,705 | 2,996 | 3,641 | 3,442 | 3,085 | 2,714 |
| Reference price 2 | 108.80 | 67.06 | 58.98 | 49.31 | 62.40 | 70.28 | 70.28 | 70.28 |
| Nbr of stocks (in thousands) | 192,035 | 192,365 | 192,194 | 188,049 | 176,864 | 174,751 | - | - |
| Announcement Date | 2/22/22 | 3/1/23 | 2/27/24 | 1/30/25 | 1/29/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 34.29x | 6.01x | 18.57x | 0.96% | 49.18B | |
| -23.34x | 351.51x | -21.46x | -.--% | 39.58B | |
| 46.99x | 4.73x | 30.33x | -.--% | 34.69B | |
| 25.1x | 2.78x | 12.03x | -.--% | 34.42B | |
| 27.15x | 7.96x | 19.98x | 0.42% | 27.11B | |
| 31.75x | 5.12x | 23.3x | -.--% | 15.36B | |
| 24.03x | 1.91x | 11.58x | -.--% | 13.02B | |
| -32.61x | 124.59x | -35.46x | -.--% | 11.76B | |
| Average | 16.67x | 63.08x | 7.36x | 0.17% | 28.14B | |
| Weighted average by Cap. | 19.59x | 72.19x | 9.61x | 0.26% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ERF Stock
- ESF Stock
- Valuation Eurofins Scientific SE
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
